Prospective Grant of Exclusive Patent License: Inhibition of Plasmodial Surface Anion Channels for the Treatment or Prevention of Malaria, 10025 [2017-02673]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
Dated: February 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02727 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Inhibition of Plasmodial
Surface Anion Channels for the
Treatment or Prevention of Malaria
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to
Microbiotix, Inc. (‘‘Microbiotix’’)
located in Worcester, Massachusetts.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before February
24, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Peter
Tung, Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 6D,
MSC9804, Rockville, MD 20852–9804
Telephone: (301) 496–2644; Facsimile:
(240) 627–3117; Email: peter.tung@
nih.gov.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Intellectual Property
United States Provisional Patent
Application No. 61/083,000, filed July
23, 2008 and entitled ‘‘Inhibitors of the
Plasmodial Surface Anion Channel as
Antimalarials’’ [HHS Reference No. E–
202–2008/0–US–01]; PCT Patent
Application PCT/US09/50637, filed July
15, 2009 and entitled ‘‘Inhibitors of the
Plasmodial Surface Anion Channel as
Antimalarials’’ [HHS Reference No. E–
202–2008/0–PCT–02]; and U.S. and
VerDate Sep<11>2014
18:11 Feb 08, 2017
Jkt 241001
foreign patent applications claiming
priority to the aforementioned
applications.
United States Provisional Patent
Application No. 61/474,583, filed April
12, 2011 and entitled ‘‘Plasmodial
Surface Anion Channel Inhibitors for
the Treatment of Malaria’’ [HHS
Reference No. E–145–2011/0–US–01];
PCT Patent Application PCT/US12/
33072, filed April 11, 2012 and entitled
‘‘Plasmodial Surface Anion Channel
Inhibitors for the Treatment of Malaria’’
[HHS Reference No. E–202–2008/0–
PCT–02]; and U.S. and foreign patent
applications claiming priority to the
aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘Methods
of preventing and/or treating malaria
infection by inhibition of Plasmodium
Surface Anion Channels (PSAC) with
anti-PSAC compounds.’’
This technology discloses a novel
anion channel on the surface of red
blood cells (RBCs) in animals infected
with Plasmodium. Named PSAC for
‘‘plasmodium surface anion channel,’’
this channel protein facilitates the
transport of nutrients into RBCs for the
plasmodium parasite. Sugars, amino
acids, purines, vitamins, and precursors
for phospholipid biosynthesis have
markedly increased uptake into infected
RBCs via PSAC. Many of these nutrients
have negligible uptake in uninfected
RBCs. PSACs, which allow nutrients to
reach the growing plasmodium parasites
inside RBCs, therefore serves as a new
target for the development of
antimalarial compounds. The disclosed
anti-PSAC compositions and methods of
using these anti-PSAC compounds
provide a means for prevention or
treatment of malaria infection by
blocking nutrients to plasmodium
parasites.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
10025
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–02673 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Geological Survey
[17 GX17CJ00GKC0100]
Notice of an Open Meeting of the
Advisory Committee on Water
Information
United States Geological
Survey, Department of the Interior.
ACTION: Notice of an open meeting of the
Advisory Committee on Water
Information (ACWI).
AGENCY:
Notice is hereby given of a
meeting of the ACWI. This meeting is to
discuss broad policy-related topics
relating to national water initiatives,
and the development and dissemination
of water information, through reports
from ACWI subgroups. The agenda will
include updates from ACWI’s various
subcommittees, unveiling of the
strategic plan for the Water Quality
Portal for 2017–2021, a proposal for a
new Terms of Reference document for
the Subcommittee on Ground Water, a
proposal to establish a new Risk
Management Workgroup within the
Subcommittee on Hydrology, an update
on activities and accomplishments
related to the Open Water Data
Initiative, and a report on the
Hydrologic Frequency Analysis Work
Group’s progress on Bulletin 17C,
Guidelines For Determining Flood Flow
Frequency.
The ACWI was established under the
authority of the Office of Management
and Budget Memorandum M–92–01 and
the Federal Advisory Committee Act.
The purpose of the ACWI is to provide
a forum for water information users and
professionals to advise the Federal
Government on activities and plans that
may improve the effectiveness of
meeting the Nation’s water information
needs. Member organizations help to
foster communications between the
Federal and non-Federal sectors on
sharing water information.
SUMMARY:
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Page 10025]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02673]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Inhibition of
Plasmodial Surface Anion Channels for the Treatment or Prevention of
Malaria
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive
Commercialization Patent License to practice the inventions embodied in
the Patents and Patent Applications listed in the Summary Information
section of this notice to Microbiotix, Inc. (``Microbiotix'') located
in Worcester, Massachusetts.
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Allergy and Infectious
Diseases' Technology Transfer and Intellectual Property Office on or
before February 24, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Commercialization
Patent License should be directed to: Peter Tung, Technology Transfer
and Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804 Telephone:
(301) 496-2644; Facsimile: (240) 627-3117; Email: peter.tung@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 61/083,000, filed
July 23, 2008 and entitled ``Inhibitors of the Plasmodial Surface Anion
Channel as Antimalarials'' [HHS Reference No. E-202-2008/0-US-01]; PCT
Patent Application PCT/US09/50637, filed July 15, 2009 and entitled
``Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials''
[HHS Reference No. E-202-2008/0-PCT-02]; and U.S. and foreign patent
applications claiming priority to the aforementioned applications.
United States Provisional Patent Application No. 61/474,583, filed
April 12, 2011 and entitled ``Plasmodial Surface Anion Channel
Inhibitors for the Treatment of Malaria'' [HHS Reference No. E-145-
2011/0-US-01]; PCT Patent Application PCT/US12/33072, filed April 11,
2012 and entitled ``Plasmodial Surface Anion Channel Inhibitors for the
Treatment of Malaria'' [HHS Reference No. E-202-2008/0-PCT-02]; and
U.S. and foreign patent applications claiming priority to the
aforementioned applications.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: ``Methods of preventing and/or
treating malaria infection by inhibition of Plasmodium Surface Anion
Channels (PSAC) with anti-PSAC compounds.''
This technology discloses a novel anion channel on the surface of
red blood cells (RBCs) in animals infected with Plasmodium. Named PSAC
for ``plasmodium surface anion channel,'' this channel protein
facilitates the transport of nutrients into RBCs for the plasmodium
parasite. Sugars, amino acids, purines, vitamins, and precursors for
phospholipid biosynthesis have markedly increased uptake into infected
RBCs via PSAC. Many of these nutrients have negligible uptake in
uninfected RBCs. PSACs, which allow nutrients to reach the growing
plasmodium parasites inside RBCs, therefore serves as a new target for
the development of antimalarial compounds. The disclosed anti-PSAC
compositions and methods of using these anti-PSAC compounds provide a
means for prevention or treatment of malaria infection by blocking
nutrients to plasmodium parasites.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Institute of Allergy and Infectious Diseases receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Commercialization Patent
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-02673 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P
